CancerDrs

Lung Cancer clinical trials in Indiana

25 actively recruiting lung cancer trials at 12 sites across Indiana.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Indiana:
  • Northwest Cancer Center - Crown Point — Crown Point, Indiana
  • Northwest Oncology LLC — Dyer, Indiana
  • Northwest Cancer Center - Hobart — Hobart, Indiana
  • Saint Mary Medical Center — Hobart, Indiana
  • The Community Hospital — Munster, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Indiana:
  • Goshen Center for Cancer Care — Goshen, Indiana
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Indiana:
  • IU Health West Hospital — Avon, Indiana
  • IU Health North Hospital — Carmel, Indiana
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Indiana:
  • Riley Hospital for Children — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Indiana:
  • Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana
  • Franciscan Health — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Indiana:
  • Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana
  • Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Franciscan Health — Indianapolis, Indiana
  • Community Cancer Center North — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Indiana:
  • Research Site — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Indiana:
  • Research Site — Noblesville, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Indiana:
  • Franciscan Health ( Site 0219) — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Hematology Oncology of Indiana — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Indiana:
  • Goshen Center for Cancer Care /ID# 257734 — Goshen, Indiana
  • Investigative Clinical Research of Indiana - Indianapolis /ID# 260468 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a…

Sponsor: AbbVie
NCT ID: NCT07155187
Sites in Indiana:
  • Parkview Research Center /ID# 277651 — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disea…

Sponsor: AbbVie
NCT ID: NCT06772623
Sites in Indiana:
  • Parkview Comprehensive Cancer Center /ID# 271879 — Fort Wayne, Indiana
  • Community Health Network /ID# 273437 — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Indiana:
  • Community Health Network — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Indiana:
  • University of Indiana — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be rand…

Sponsor: Greg Durm, MD
NCT ID: NCT04317534
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side eff…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07154290
Sites in Indiana:
  • Franciscan Health — Munster, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT07155174
Sites in Indiana:
  • Fort Wayne Medical Oncology And Hematology /ID# 277336 — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Indiana:
  • UChicago Medicine - Northwest Indiana — Crown Point, Indiana
  • Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
  • Community Health Network, Inc — Indianapolis, Indiana
  • Community Health Network, Inc. — Indianapolis, Indiana
  • Community Health Network Investigational Drug Services — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Sponsor: Compass Therapeutics
NCT ID: NCT06150664
Sites in Indiana:
  • Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
View on ClinicalTrials.gov →
Recruiting Industry

GEMINI-NSCLC: NSCLC Biomarker Study

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and di…

Sponsor: Tempus AI
NCT ID: NCT05236114
Sites in Indiana:
  • Community Health Network — Indianapolis, Indiana
View on ClinicalTrials.gov →
NA Recruiting Federal

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effec…

Sponsor: VA Office of Research and Development
NCT ID: NCT02984761
Sites in Indiana:
  • Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer

This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.

Sponsor: Indiana University
NCT ID: NCT05889546
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
  • Roudebush VA Medical Center — Indianapolis, Indiana
  • Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Increasing Equity in Lung Cancer Screening

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating t…

Sponsor: Indiana University
NCT ID: NCT06360822
Sites in Indiana:
  • Eskenazi Health — Indianapolis, Indiana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10